User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

[Current management of myelodysplastic syndromes].

Primary tabs

Caers, J Bonnet, C Graux, Carlos [UCL] De Prijck, B Beguin, Y

Treatment of myelodysplastic syndromes (MDS) has improved in recent years with better results of allogeneic stem cell therapy (SCT), the advent of new therapeutic options such as hypomethylating agents and lenalidomide, the introduction of iron chelation therapy and the implication of erythropoietic stimulating agents in the treatment of anemia. In this review, we summarize the different diagnostic and prognostic criteria and outline the different treatment options we have in 2011.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2011
Language Français
Journal information "Revue médicale suisse" - Vol. 7, no. 306, p. 1634 (2011)
Peer reviewed yes
issn 1660-9379
Publication status Publié
Affiliations UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - (MGD) Service d'hématologie
MESH Subject Algorithms ; Humans ; Myelodysplastic Syndromes
Links
Bibliographic reference Caers, J ; Bonnet, C ; Graux, Carlos ; De Prijck, B ; Beguin, Y. [Current management of myelodysplastic syndromes].. In: Revue médicale suisse, Vol. 7, no. 306, p. 1634 (2011)
Permanent URL http://hdl.handle.net/2078.1/123320